Experts question Huidagene's transparency following fatal trial incident
Experts are questioning the transparency of biotech company Huidagene following a patient's death. The scrutiny focuses on whether the firm fully disclosed relevant safety data. The case highlights concerns about clinical trial reporting.
Related stories
Fatal outcome surfaces in Chinese gene therapy study, raising transparency concerns · Drug development
Fatal trial incidents in China cast doubt on rapid review process · Drug development
Debate over optimal cancer drug dosing intensifies · Cancer research
Amylyx's avexitide hits Phase 3 goal in post-bariatric hypoglycemia · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “STAT+: Experts scrutinize Huidagene’s disclosures after patient death.” Browse more stories.